rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ARVN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Arvinas at Jefferies Global Healthcare Conference: pipeline takes center stage
      18h agoInvesting.comARVNJEF
      Arvinas vp David Loomis sells $1,475 in stock
      Nov 9Investing.comARVN
      Arvinas to present ARV-393 lymphoma trial data at ASH meeting
      Nov 4Investing.comARVN
      Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
      Nov 4Yahoo FinanceARVN
      H.C. Wainwright cuts Arvinas stock price target to $13 from $18
      Nov 4Investing.comARVN
      What Arvinas Bears Saw Before The Fall
      Nov 4Yahoo FinanceARVN
      Arvinas Inc (ARVN) (Q3 2026) Earnings Call Highlights: Cost Cuts, $558. ...
      Nov 4Yahoo FinanceARVN
      Arvinas (ARVN) Q3 2026 Earnings Call Transcript
      Nov 3The Globe and MailARVN
      What Arvinas (ARVN) Said on Its Q3 Earnings Call

      Arvinas (NASDAQ:ARVN) outlined upcoming clinical milestones across its oncology and neurology pipeline during its third-quarter 2026 earnings call, while reporting lower operating expenses and a cash runway projected into the second half of 2028. President and CEO Randy Teel said the company is pri

      Nov 3Yahoo FinanceARVN
      Arvinas Q3 2026 Earnings Call Transcript
      Nov 3BenzingaARVN
      Earnings call transcript: Arvinas Q3 2026 loss narrows, revenue misses sharply
      Nov 3Investing.comARVN
      Arvinas earnings beat by $0.03, revenue fell short of estimates
      Nov 3Investing.comARVN
      Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates
      Nov 3Yahoo FinanceARVN
      What To Expect From Arvinas Inc (ARVN) Q3 2026 Earnings
      Nov 2Yahoo FinanceARVN
      Reasons Why Investors Should Consider Betting on Arvinas Stock

      ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.

      Oct 13Yahoo FinanceARVN
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Arvinas Holding Company (ARVN) and Ovid Therapeutics (OVID)

      Detailed price information for Ovid Therapeutics Inc (OVID-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailARVNOVIDBHC
      Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Arvinas Holding Company (ARVN) and Halozyme (HALO)

      Detailed price information for Arvinas Inc (ARVN-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailARVNHALO
      Arvinas presents phase 1 data for Parkinson’s drug ARV-102
      Oct 7Investing.comARVN
      Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
      Oct 7Yahoo FinanceARVN
      Arvinas to present ARV-102 Parkinson’s data at MDS congress
      Oct 1Investing.comARVN
      Arvinas doses first patient in ARV-6723 cancer trial
      Sep 28Investing.comARVN
      Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

      – ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC)

      Sep 28Yahoo FinanceARVN
      Arvinas Q2 2026 Earnings Call Transcript - Arvinas (NASDAQ:ARVN)

      Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings

      Sep 25BenzingaARVN
      Arvinas at Morgan Stanley conference: pipeline focus, capital discipline
      Sep 16Investing.comARVNMS
      Arvinas at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline takes center stage
      Sep 10Investing.comARVN
      Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod

      On August 4, Arvinas Inc. (NASDAQ:ARVN) reported second-quarter 2026 financial results and a corporate update that doubled as one of the more consequential updates in the company’s history. The clinical-stage biotech disclosed the first-ever FDA approval of a PROTAC, a heterobifunctional protein degrader, alongside a licensing deal that hands off commercial duties to another drugmaker. […]

      Sep 9Yahoo FinanceARVN
      Arvinas at Wells Fargo conference: pipeline nears key data
      Sep 8Investing.comARVNWFC
      Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock inc

      Sep 1Yahoo FinanceARVN
      Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish (NASDAQ:ARVN)
      Aug 28Seeking AlphaARVN

      This is the newest page. Registered accounts read further back.